• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Paranjape Ketan

    1/8/25 8:39:43 PM ET
    $SYRA
    Diversified Commercial Services
    Consumer Discretionary
    Get the next $SYRA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Paranjape Ketan

    (Last) (First) (Middle)
    C/O SYRA HEALTH CORP.
    1119 KEYSTONE WAY N., #201

    (Street)
    CARMEL IN 46032

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Syra Health Corp [ SYRA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/07/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Options $0.7386 01/07/2025 A 15,170 (1) 01/07/2035 Class A Common Stock 15,170 $0 34,473 D
    Explanation of Responses:
    1. The options were issued pursuant to the Issuer's 2022 Omnibus Equity Incentive Plan and vest as follows: (i) 25% of the options vested immediately on the date of grant and (ii) the balance of the options shall vest in 12 equal monthly installments.
    /s/ Deepika Vuppalanchi, as Attorney-in-Fact for Ketan Paranjape 01/08/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $SYRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Rogers Sherron

      4 - Syra Health Corp (0001922335) (Issuer)

      1/8/25 8:39:45 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Dahlem Andrew

      4 - Syra Health Corp (0001922335) (Issuer)

      1/8/25 8:39:48 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • SEC Form 4 filed by Director Paranjape Ketan

      4 - Syra Health Corp (0001922335) (Issuer)

      1/8/25 8:39:43 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    SEC Filings

    See more
    • Syra Health Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Syra Health Corp (0001922335) (Filer)

      5/20/25 4:30:24 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Syra Health Corp (0001922335) (Filer)

      5/8/25 4:45:37 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • SEC Form 10-Q filed by Syra Health Corp.

      10-Q - Syra Health Corp (0001922335) (Filer)

      5/8/25 4:30:29 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Syra Health Selected for $5.8 Million Indiana Child Mental Health Program

      CARMEL, Ind., May 27, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that the Indiana Department of Administration in collaboration with the Family and Social Services Administration/Division of Mental Health and Addiction has recommended Syra Health for contract negotiations to implement Indiana's Child Mental Health Wraparound Access Site. The contract is valued at $5.8 million over three years, with an optional one-year extension. Syra has committed to subcontracting 23.5% of the total contract value to other Indian

      5/27/25 8:55:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health Board Begins CEO Search to Drive Growth

      CARMEL, Ind., May 20, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that its Board of Directors will begin a national search for a new Chief Executive Officer to succeed current CEO Dr. Deepika Vuppalanchi. Dr. Vuppalanchi will serve as interim CEO until a successor is appointed. This leadership transition is part of a strategic succession plan designed to position Syra Health for its next phase of grow

      5/20/25 9:00:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health Announces First Quarter Revenue of $1.9 Million, Up 6% YoY

      Revenue increase led by Population Health's 261% YoY Expansion Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY Continued Efficiency Gains Cut Q1 2025 Net Losses by Over Two Thirds Compared to Q1 2024 A conference call will be held today, Thursday, May 8, at 9:00 am ET CARMEL, Ind., May 8, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for the first quarter ended March 31, 2025.

      5/8/25 7:55:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Financials

    Live finance-specific insights

    See more
    • Syra Health Announces First Quarter Revenue of $1.9 Million, Up 6% YoY

      Revenue increase led by Population Health's 261% YoY Expansion Gross Margin Improves Substantially to 31.7%, up 14.6 Percentage Points YoY Continued Efficiency Gains Cut Q1 2025 Net Losses by Over Two Thirds Compared to Q1 2024 A conference call will be held today, Thursday, May 8, at 9:00 am ET CARMEL, Ind., May 8, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for the first quarter ended March 31, 2025.

      5/8/25 7:55:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health To Discuss First Quarter 2025 Financial Results

      Conference call will be held on Thursday, May 8, at 9:00 a.m. ET CARMEL, Ind., May 1, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA), ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that it will report financial results for the three months ended March 31, 2025, on Thursday, May 8, 2025, before market open. The Company will host a conference call that same day, May 8, 2025, at 9:00 a.m. ET, to discuss the results. Interested parties can access the con

      5/1/25 8:55:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary
    • Syra Health Announces Full-Year Revenue of $8.0 Million, Up 45% YoY

      2024 Population Health Revenue Acceleration to 132% YoY Q4 2024 Net Losses Cut Nearly in Half Compared to Q4 2023, Highlighting Major Efficiency Gains Continued Momentum with New Customer Wins and Contract Extensions Driving Sustainable Growth A conference call will be held today, Tuesday, March 11 at 9:00 am ET CARMEL, Ind., March 11, 2025 /PRNewswire/ -- Syra Health Corp. (NASDAQ:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today its financial results for fourth quarter and full year ended December 31, 2024.

      3/11/25 7:43:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Syra Health Corp.

      SC 13G - Syra Health Corp (0001922335) (Subject)

      2/20/24 3:01:17 PM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Syra Health Board Begins CEO Search to Drive Growth

      CARMEL, Ind., May 20, 2025 /PRNewswire/ -- Syra Health Corp. (OTCQB:SYRA) ("Syra Health" or the "Company"), a healthcare technology company dedicated to powering better health through innovative technology products and services, announced today that its Board of Directors will begin a national search for a new Chief Executive Officer to succeed current CEO Dr. Deepika Vuppalanchi. Dr. Vuppalanchi will serve as interim CEO until a successor is appointed. This leadership transition is part of a strategic succession plan designed to position Syra Health for its next phase of grow

      5/20/25 9:00:00 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary

    $SYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO and COO Prasad Priya bought $13,257 worth of shares (14,448 units at $0.92) and sold $10,144 worth of shares (4,153 units at $2.44) (SEC Form 4)

      4 - Syra Health Corp (0001922335) (Issuer)

      9/13/24 9:10:53 AM ET
      $SYRA
      Diversified Commercial Services
      Consumer Discretionary